Shots: The ongoing P-IIIb VISIBLE OLE study involves assessing of Entyvio (SC) in adult patients with UC or CD, following enrolment and participation in the VISIBLE 1 (UC) or VISIBLE […]readmore
Tags : During
Shots: The approval is based on P-I/II ARROW study assessing Gavreto (400mg, qd) in RET fusion-positive NSCLC patients with or without prior therapy, and regardless of RET fusion partner or […]readmore
Shots: VIVUS has accelerated the launch of the telemedicine and remote monitoring modules of the VIVUS Health Platform, will enable physicians to utilize it in conducting virtual office visits, regardless […]readmore
Shots: The US FDA has issued guidance to aid sponsors & IRBs for assuring the safety of participants in clinical studies, maintaining compliance with GCP and to reduce the risk […]readmore
Pharma
Regulatory
Novartis’ LysaKare (arginine hydrochloride/lysine hydrochloride) Solution Receives CHMP’s Positive Opinion
Shots: The positive opinion recommendation follows the study assessing arginine and lysine of same content as LysaKare, evaluating its safety and efficacy The EC will review CHMP’s opinion with its […]readmore